CIT GAP Funds makes seed-stage equity investments in Virginia-based technology and life science companies with a high potential for achieving rapid growth and generating significant economic return.
Overview
CIT GAP Funds makes seed-stage equity investments in Virginia-based technology and life science companies with a high potential for achieving rapid growth and generating significant economic return. CIT’s family of funds includes:
- GAP I – A vintage 2004 fund fully invested in a broad array of seed-stage technology companies. Portfolio.
Based on the success of GAP I, CIT launched two specialized follow-on funds in 2007.
- GAP BioLife – A seed fund investing exclusively in life science companies.
- GAP Tech – A seed fund investing in IT and technology companies.
For investment criteria click here.
GAP Fund Highlights
- Verical was acquired by Arrow Electronis on 4/6/10
- Soft Tissue Regeneration closed a Series A round on 6/30/09
- Secure Command closed a Series A on 3/12/09
- South49 closed Series A round on 2/4/09
- KZO Innovations closed a Series A round on 11/14/08
- RollStream closed a Series B round on 10/27/08
- Mpowerplayer closed a Series A round on 9/9/08
- Global Cell Solutions closed a Series A round on 4/22/08
- SquareLoop closed a Series A round on 12/17/07
- Tau Therapeutics closed a Series A round on 10/19/07
- Verical closed a Series A round on 9/27/07
- OnDialog closed a Series A round on 4/13/07
- 4FrontSecurity was acquired by Symantec on 2/23/07
- Visure closed a Series A round on 2/22/07
- RollStream closed a Series A round on 7/17/06
- Paxfire closed a Series A round on 4/22/05